SlidesetViral Hepatitis and Liver DiseaseMethods of MR fat quantification and their pros and cons | Michael Middleton, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseNoninvasive imaging methods for assessment of liver damage in NASH | Bachir Taouli, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseO_04 - Blood-based Protein Biomarkers of NASH | Dr. S. WilliamsView Slideset
SlidesetViral Hepatitis and Liver DiseaseO_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease | Dr. P. EddowesView Slideset
SlidesetViral Hepatitis and Liver DiseaseLiverMultiScan – quantitative MR imaging for NASH | Rajarshi BanerjeeView Slideset
SlidesetViral Hepatitis and Liver DiseaseO_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. SanyalView Slideset
SlidesetViral Hepatitis and Liver DiseaseNeed for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MDView Slideset
SlidesetViral Hepatitis and Liver DiseasePrinciples of Biomarker Development | Margery Connelly, PhD, MBAView Slideset
SlidesetViral Hepatitis and Liver DiseaseQuantitative measures of liver health | Grey Everson, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseDefining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBSView Slideset
SlidesetViral Hepatitis and Liver DiseaseO_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study | Dr. P. EddowesView Slideset
SlidesetViral Hepatitis and Liver DiseaseBiomarkers: what can be learned from type 2 diabetes | Manu Chakravarthy, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseProteomics-based biomarker discovery in NAFLD | Naga Chalasani, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseStudy Design and endpoints in Omics-based biomarker studies | Stephen Williams, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseLipid and Bile acids as NAFLD-related biomarkers | Puneet Puri, MBBS, MDView Slideset
SlidesetViral Hepatitis and Liver DiseasePotential approach to identify the NAFLD patient who will develop HCC | Yujin Hoshida, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseBiomarker development in pediatric NAFLD: special challenges in a special population | Saul Karpen, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseDynamic measurement of physiologic functions: any role in NASH diagnostics | Stephen Previs, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseMicrobiome: diagnostic considerations | Patrick GillevetView Slideset
SlidesetViral Hepatitis and Liver DiseaseO_03 - A non-invasive lipidomic test accurately discriminates NASH from steatosis: a blind validation study | Dr. T. MontgomeryView Slideset